Physician profile
Helen Yang
NPI 1255629440
$5,141.24
in general payments reported to CMS, 2019-2025
30 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $1,101 · 2021: $1,204 · 2022: $429 · 2023: $626 · 2024: $490 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.03 | 2019-2023 | Lo Loestrin Fe |
| Aspira Women'S Health INC | $530.72 | 2020-2024 | Ova1 |
| Exeltis, USA INC. | $438.25 | 2020-2025 | Slynd, Nuvessa, Solosec |
| Mayne Pharma Commercial LLC | $317.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $271.71 | 2019-2023 | |
| Therapeuticsmd, INC. | $225.31 | 2019-2021 | |
| Minerva Surgical, INC | $200.87 | 2019-2020 | |
| Myovant Sciences INC. | $181.33 | 2021-2022 | |
| Pfizer INC. | $162.21 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $156.61 | 2023-2025 | Myfembree |
| Davol INC. | $145.38 | 2020 | |
| Lupin INC. | $138.86 | 2019-2020 | |
| Organon LLC | $137.57 | 2023-2024 | Nexplanon |
| Bard Access Systems, INC. | $129.91 | 2019 | |
| Allergan, INC. | $111.98 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $103.87 | 2023-2025 | Vistaseal, Ethicon, Stratafix |
| Merck Sharp & Dohme LLC | $102.03 | 2019-2021 | |
| Avion Pharmaceuticals | $93.49 | 2019-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $93.34 | 2022-2023 | Fluent Fluid Management System, Aptima |
| Medtronic, INC. | $71.89 | 2022-2024 | Ligasure |
| Sage Therapeutics, LLC | $64.41 | 2025 | Zurzuvae |
| Horizon Therapeutics Plc | $57.72 | 2019 | |
| Radius Health, INC. | $44.99 | 2019-2020 | |
| Becton, Dickinson and Company | $40.45 | 2019 | |
| Ascend Therapeutics US, LLC | $39.80 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.80 | 2019 | |
| Channel Medsystems, INC. | $16.63 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.63 | 2019 | |
| Coopersurgical, INC. | $14.99 | 2025 | Paragard T 380a |
| Duchesnay USA Incorporated | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.